Voyager Therapeutics, Inc.
VYGR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $275 | $182 | $197 | $329 |
| - Cash | $45 | $44 | $75 | $71 |
| + Debt | $38 | $40 | $42 | $44 |
| Enterprise Value | $268 | $179 | $164 | $301 |
| Revenue | $13 | $5 | $6 | $6 |
| % Growth | 157% | -19.7% | 3.1% | – |
| Gross Profit | $13 | $5 | $6 | $6 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$27 | -$36 | -$34 | -$37 |
| % Margin | -201.1% | -683.8% | -520.3% | -593.9% |
| Net Income | -$28 | -$33 | -$31 | -$34 |
| % Margin | -208.7% | -642% | -479.2% | -549.3% |
| EPS Diluted | -0.47 | -0.57 | -0.53 | -0.59 |
| % Growth | 17.5% | -7.5% | 10.2% | – |
| Operating Cash Flow | -$31 | -$33 | -$38 | -$15 |
| Capital Expenditures | -$0 | -$1 | -$1 | -$0 |
| Free Cash Flow | -$31 | -$34 | -$39 | -$15 |